Cystic Fibrosis Drug by Pharmaxis Requires Another Trial to Get FDA Approval

by Raja Nandhini on  March 21, 2013 at 7:32 AM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

FDA has denied approval to market the drug, Bronchitol, manufactured by the Australian biotechnology company, Pharmaxis, in US market.
 Cystic Fibrosis Drug by Pharmaxis Requires Another Trial to Get FDA Approval
Cystic Fibrosis Drug by Pharmaxis Requires Another Trial to Get FDA Approval

The dry powder formulation of mannitol (Bronchitol) is designed to treat cystic fibrosis. It is approved in Australia for patients above six years of age and for adults above 18 years old in European Union.

The review committee has rejected the approval stating that an additional trial is required to prove the efficacy of the drug. FDA has noted that the first two clinical trial data submitted by the company do not meet benefit- risk balance. The first trial had too many early dropouts while the second study failed to produce statistically significant results.

Gary Phillips, CEO of Pharmaxis has announced that the company is ready to work with FDA and take the required measured to gain approval.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Drug Toxicity Signature Drug Toxicity Genetic Testing of Diseases Cystic Fibrosis Fibroscan for Fatty Liver Cirrhosis and Fibrosis Retroperitoneal Fibrosis / Ormondīs Disease 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive